ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS‑001 in Relapsed or Refractory Advanced Solid Tumors

ImmunoGenesis today announced the first patient has been dosed in the company’s Phase 1a/1b clinical trial of its lead candidate, IMGS-001, at The University of Texas MD Anderson Cancer Center in Houston, Texas. IMGS-001 is a dual-specific programmed cell death 1 ligand 1 (PD-L1)/programmed cell death 1 ligand 2 (PD-L2) antibody engineered with cytotoxic function designed to treat cold, immune-excluded tumors, which are resistant to existing immunotherapy.

Read more
ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for Relapsed or Refractory Advanced Solid Tumors

ImmunoGenesis and Cancer Focus Fund, LP, announce that Cancer Focus Fund plans to invest $4.5 million to support the Phase 1a/1b clinical trial of ImmunoGenesis’ lead candidate, IMGS-001. The investment will support the portion of the IMGS-001 Phase 1a/1b multi-site clinical trial being conducted at MD Anderson. It coincides with ImmunoGenesis’ Series A financing, which is expected to close in the third quarter.

Read more
ImmunoGenesis Announces Positive Preclinical Glioblastoma and Pancreatic Cancer Data for STimulator of INterferon Genes (STING) Agonist Published in Two Scientific Journals

•STING agonist can induce innate immune responses that allow the immune system to fight otherwise immunologically resistant cancers
•Phase 1 canine glioblastoma veterinary trial data show the promise of STING agonist as potential future therapy for human glioblastoma
•Data support the advancement of ImmunoGenesis’ STING-Immune Stimulating Antibody Conjugate (ISAC) in immunologically cold tumors

Read more